Adults hospitalized for RSV face higher odds of cardiac complications than those with COVID-19 or influenza, especially in ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections in infants ...

A single injection of nirsevimab, a long-acting monoclonal antibody developed to prevent respiratory syncytial virus (RSV) ...

Respiratory Syncytial Virus (RSV) poses a significant threat to Indian infants, particularly during post-monsoon and winter, ...

World Health Organisation (WHO) has identified the new COVID variant, NB.1.8.1, detected in January, as a descendant of ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug ...

As society becomes more relaxed about the perceived threat of Covid-19, the coronavirus has started to resurge in many ...

A single dose of the long-acting antibody nirsevimab to infants can halve hospitalizations for bronchiolitis.

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug has been approved at the ...

Respiratory syncytial virus (RSV) infection is the leading cause of hospitalisation for respiratory diseases among children under 5 years old. The aim of this study was to analyse RSV seasonality in ...

RSV leads to over 100,000 infant deaths annually, but WHO’s latest guidance recommends maternal vaccines and monoclonal ...

Discover a study that highlights the importance of identifying high-risk children through biomarkers and better understanding ...